悪性神経膠腫(Malignant Glioma):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Malignant Glioma - Pipeline Review, H2 2014
◆商品コード:GMDHC5820IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年12月10日
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における悪性神経膠腫(Malignant Glioma)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・悪性神経膠腫(Malignant Glioma)の概要
・悪性神経膠腫(Malignant Glioma)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・悪性神経膠腫(Malignant Glioma)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・悪性神経膠腫(Malignant Glioma)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・悪性神経膠腫(Malignant Glioma)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Malignant Glioma – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Malignant Glioma – Pipeline Review, H2 2014’, provides an overview of the Malignant Glioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malignant Glioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Malignant Glioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Malignant Glioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Malignant Glioma Overview 7
Therapeutics Development 8
Pipeline Products for Malignant Glioma – Overview 8
Pipeline Products for Malignant Glioma – Comparative Analysis 9
Malignant Glioma – Therapeutics under Development by Companies 10
Malignant Glioma – Therapeutics under Investigation by Universities/Institutes 11
Malignant Glioma – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Malignant Glioma – Products under Development by Companies 15
Malignant Glioma – Products under Investigation by Universities/Institutes 16
Malignant Glioma – Companies Involved in Therapeutics Development 17
Advantagene, Inc. 17
Eli Lilly and Company 18
Lipopharma Therapeutics SL 19
Nuo Therapeutics, Inc. 20
Orbus Therapeutics, Inc. 21
Sanofi 22
Stemline Therapeutics, Inc. 23
ZIOPHARM Oncology, Inc. 24
Malignant Glioma – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
Ac-929C – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Ad-RTS-IL-12 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ALD-451 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Dendritic Cell Therapy for Malignant Gliomas – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Dendritic Cell Therapy for Oncology – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Dendritic Cell Therapy for Oncology – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Dendritic Cell Therapy for Oncology – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
eflornithine hydrochloride – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
galunisertib – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
GliAtak – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
IDD-004 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
LD-224 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Minerval – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Oncolytic Virus for Oncology – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SL-701 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule for Brain Cancer and Malignant Glioma – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Vaccine to Target Survivin for Malignant Glioma – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
voxtalisib – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
WT-1 Peptide Vaccine – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Malignant Glioma – Recent Pipeline Updates 61
Malignant Glioma – Dormant Projects 67
Malignant Glioma – Discontinued Products 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70

[List of Tables]
Number of Products under Development for Malignant Glioma, H2 2014 8
Number of Products under Development for Malignant Glioma - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Malignant Glioma - Pipeline by Advantagene, Inc., H2 2014 17
Malignant Glioma - Pipeline by Eli Lilly and Company, H2 2014 18
Malignant Glioma - Pipeline by Lipopharma Therapeutics SL, H2 2014 19
Malignant Glioma - Pipeline by Nuo Therapeutics, Inc., H2 2014 20
Malignant Glioma - Pipeline by Orbus Therapeutics, Inc., H2 2014 21
Malignant Glioma - Pipeline by Sanofi, H2 2014 22
Malignant Glioma - Pipeline by Stemline Therapeutics, Inc., H2 2014 23
Malignant Glioma - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Malignant Glioma Therapeutics - Recent Pipeline Updates, H2 2014 61
Malignant Glioma - Dormant Projects, H2 2014 67
Malignant Glioma - Discontinued Products, H2 2014 68

[List of Figures]
Number of Products under Development for Malignant Glioma, H2 2014 8
Number of Products under Development for Malignant Glioma - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Top 10 Targets, H2 2014 26
Number of Products by Stage and Top 10 Targets, H2 2014 27
Number of Products by Top 10 Mechanism of Actions, H2 2014 28
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 29
Number of Products by Top 10 Routes of Administration, H2 2014 30
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 31
Number of Products by Top 10 Molecule Types, H2 2014 32
Number of Products by Stage and Top 10 Molecule Types, H2 2014 33

【掲載企業】

Advantagene, Inc.
Eli Lilly and Company
Lipopharma Therapeutics SL
Nuo Therapeutics, Inc.
Orbus Therapeutics, Inc.
Sanofi
Stemline Therapeutics, Inc.
ZIOPHARM Oncology, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[悪性神経膠腫(Malignant Glioma):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆